Viela Bio a clinical-stage biotechnology company focused on treatments for autoimmune and inflammatory diseases. Co.'s pipeline includes nebilizumab, which Co. is developing as a potential first-line monotherapy for neuromyelitis optica spectrum disorder, VIB4920, which is a fusion protein designed to bind to CD40L on activated T cells, blocking their interaction with CD40-expressing B cells and other binding partners; and VIB7734, which is a humanized monoclonal antibody (mAb) intended to be a treatment for autoimmune diseases. Co. is also conducting pre-clinical research and development on two product candidates including VIB1116, which is a mAb and a mAb cytokine fusion protein. We show 7 historical shares outstanding datapoints in our VIE shares outstanding history coverage, used to compute VIE market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing VIE market cap history over the course of time is important for investors
interested in comparing VIE's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of VIE versus a peer is one thing; comparing
VIE market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like VIE can fluctuate over the course of history.
With this page we aim to empower investors researching VIE by allowing them to research the VIE market cap history. |
Free VIE Email Alerts:
Video: The Importance of Market Cap
